|Bid||2.06 x 900|
|Ask||2.27 x 900|
|Day's Range||2.05 - 2.30|
|52 Week Range||1.02 - 4.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
German artificial limb manufacturer Ottobock (IPO-OBH.F) plans to start selling a mechanical exoskeleton that makes manual labor for factory workers easier this week, joining a field already crowded with major industrial players and start-ups. The family-owned company has tested the 'Paexo', a wearable upper-body exoskeleton designed to ease the physical strain of repetitive overhead assembly work, on 30 workers at a Volkswagen (VOWG_p.DE) plant in Bratislava. After 80 percent of workers said they would recommend it to colleagues, Ottobock is talking to Volkswagen about using the Paexo in series production, said Soenke Roessing, head of Ottobock's Industrials unit.
Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.
NEW YORK, Aug. 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Evolent ...
Investors recently long EKSO have made 65% with more potential upside to come. Tandem Diabetes Care, Inc. (TNDM) has traded from $2 to $34/share this year, a gain of over 1700%. This is based on improving commercial success with their diabetes business and another FDA approval in the summer.
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that U.S. government’s General Services Administration (GSA) has added the company to its list of contracted Federal Business Opportunities (FBO). “We are pleased that Ekso Bionics has been added to the GSA’s listing of Federal Business Opportunities,” said Jack Peurach, President and Chief Executive Officer of Ekso Bionics. Established in 1949 with a mission to deliver value and savings in real estate, acquisition, technology, and other mission-support services across Government, the GSA is tasked with administering supplies and providing workplaces for federal employees.
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that John (Jack) Glenn has been appointed to the position of Chief Financial Officer. Mr. Glenn brings over 25 years of financial leadership experience within public and private companies in the life sciences industry. Mr. Glenn replaces Max Scheder-Bieschin, who, as previously announced, is leaving the company.
Shares of Ekso Bionics saw big gains during the trading day but lost almost 11% in after-hours trading. The company reported second quarter results that didn’t hit estimates. Spark Therapeutics, Inc. shares closed down 27.83% on Tuesday, on significant trading volume compared to usual.
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -18.18% and -2.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Richmond, California-based company said it had a loss of 13 cents. The robotic exoskeleton company posted revenue of $3 million in the period. In the final minutes of trading ...
RICHMOND, Calif., Aug. 07, 2018-- Ekso Bionics Holdings, Inc., an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June ...
Ford has rolled out a robotic vest for its factory workers that promises to lessen the physical toll that building cars and trucks takes on their bodies.
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Ekso Bionics Holdings, Inc. (NASDAQ: EKSO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...
The technology provides lift assistance to the arms to help reduce fatigue and injury risk. “Building vehicles is physically a tough job,” Bruce Hettle, Ford group vice president of Manufacturing and Labor Affairs, said in a press release. The Ford partnership was, in itself, big for Ekso.
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2018 after the close of trading on Tuesday, August 7, 2018. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers, using Conference ID: 13581989.
On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: Becton, Dickinson and Co. (NYSE: BDX), Ekso Bionics Holdings Inc. (NASDAQ: EKSO), Haemonetics Corp. (NYSE: HAE), and Hologic Inc. (NASDAQ: HOLX).
Shareholder rights law firm Robbins Arroyo LLP reminds investors that purchasers of Ekso Bionics Holdings, Inc. filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 15, 2017 and December 27, 2017.
Investors are always looking for growth in small-cap stocks like Ekso Bionics Holdings Inc (NASDAQ:EKSO), with a market cap of US$100.79m. However, an important fact which most ignore is: howRead More...
NEW YORK, NY / ACCESSWIRE / June 15, 2018 / Elon Musk is investing millions in technology to enhance and connect the brain to robots and prosthetics. Upstart NeuroOne Medical (NMTC) could change that with their first FDA approved device, anticipated by the end of this year - a thin-film electrode that was pioneered at The Mayo Clinic. This prestigious institute owns 10% of NMTC, validating the tech.
LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want a free Stock Review on TRXC sign up now at www.wallstequities.com/registration. Today's attention is redirected to the Medical Instruments and Supplies space, which comprises companies that manufacture and sell medical devices, instrument systems, and reagents and consumables.
LONDON, UK / ACCESSWIRE / May 11, 2018/ If you want a free Stock Review on EKSO sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research coverage on Ekso Bionics Holdings Inc. (NASDAQ: EKSO), Haemonetics Corp. (NYSE: HAE), Hill-Rom Holdings Inc. (NYSE: HRC), and NeuroMetrix Inc. (NASDAQ: NURO). Companies in the Medical Instruments and Supplies Manufacturing industry primarily research, develop, and produce nonelectronic medical, surgical, dental, and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, blood transfusion equipment, catheters, surgical clamps, and medical thermometers.
On a per-share basis, the Richmond, California-based company said it had a loss of 13 cents. The robotic exoskeleton company posted revenue of $2.5 million in the period. In the final minutes of trading ...